Evan Seigerman
Stock Analyst at BMO Capital
(4.19)
# 420
Out of 5,163 analysts
154
Total ratings
55.88%
Success rate
12.73%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $129.78 | +7.87% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $181.55 | +7.96% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $46.52 | +16.08% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $985.08 | +21.82% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $144.99 | -10.34% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $469.34 | +12.92% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $92.54 | -35.16% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $60.04 | +99.87% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $59.08 | +3.25% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $53.75 | -25.58% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $7.14 | +460.22% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $745.77 | +5.66% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $4.44 | -43.69% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $366.21 | -33.64% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.67 | +156.96% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.58 | +125.73% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.00 | +900.00% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $129.78
Upside: +7.87%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $181.55
Upside: +7.96%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $46.52
Upside: +16.08%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $985.08
Upside: +21.82%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $144.99
Upside: -10.34%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $469.34
Upside: +12.92%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $92.54
Upside: -35.16%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $60.04
Upside: +99.87%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $59.08
Upside: +3.25%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $53.75
Upside: -25.58%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.14
Upside: +460.22%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $745.77
Upside: +5.66%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $4.44
Upside: -43.69%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $366.21
Upside: -33.64%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.67
Upside: +156.96%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.58
Upside: +125.73%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.00
Upside: +900.00%